Table 1.

 Results of DREAM trial of treatment to prevent diabetes

End point/side effect	No (%) of participants		Hazard ratio (95% CI)
	Rosiglitazone (n=2635)	Placebo (n=2634)
Primary end point*	306 (11.6)	686 (26)	0.40 (0.35 to 0.46)
Death from all causes	30 (1.1)	33 (1.3)	0.91 (0.55 to 1.49)
Diagnosis of diabetes	280 (10.6)	658 (25)	0.38 (0.33 to 0.44)
Congestive heart failure	14 (0.5)	2 (0.1)	7.0 (1.6 to 30.9)
Oedema	174 (6.8)	124 (4.9)	Not reported

*Composite of death from all causes and diagnosis of diabetes.